Literature DB >> 18667844

Elevated expression of UBE2T in lung cancer tumors and cell lines.

Jia Hao1, Anjian Xu, Xiaolei Xie, Juanting Hao, Tian Tian, Shugeng Gao, Xueyuan Xiao, Dacheng He.   

Abstract

The aim of this study was to investigate the association between UBE2T, a member of the ubiquitin-conjugating E2 family, and lung cancer, which has never been reported to date. Therefore, the expression of UBE2T mRNA was examined in normal human tissues and 8 lung cancer cell lines. Subsequently, UBE2T expression was analyzed in 41 lung cancer tissues by PCR and Western blots, as well as in 103 lung cancer specimens by immunohistochemistry. To further elucidate the possible functional role of UBE2T, the protein was overexpressed in NIH3T3 cells. UBE2T mRNA was highly expressed in all lung cancer cell lines examined, while it could not be detected in normal lung tissue. UBE2T was detected in 75.6% of primary lung cancer tissue samples (n = 41) at mRNA level and in 60.9% at protein level. In addition, positive UBE2T staining was observed in 61% of lung cancer specimens (n = 103), particularly in all immunohistochemically stained small cell carcinoma tissues. In normal lung tissue, only weak staining was observed in the basal cells of bronchial epithelium. Overexpression of UBE2T in NIH3T3 cells significantly promoted colony formation in soft agar medium (p < 0.001). In conclusion, UBE2T was significantly upregulated in lung cancer tissue and cell lines, suggesting involvement of UBE2T in the malignant cell phenotype. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667844     DOI: 10.1159/000148187

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Ubiquitin-Conjugating Enzyme E2T is an Independent Prognostic Factor and Promotes Gastric Cancer Progression.

Authors:  Hao Yu; Pei Xiang; Qi Pan; Yijiao Huang; Nanlan Xie; Weimin Zhu
Journal:  Tumour Biol       Date:  2016-03-28

2.  Role of E3 ubiquitin ligases in lung cancer.

Authors:  Barbara C Snoek; Leonie Ham de Wilt; Gerrit Jansen; Godefridus J Peters
Journal:  World J Clin Oncol       Date:  2013-08-10

3.  Independent and functional validation of a multi-tumour-type proliferation signature.

Authors:  M H W Starmans; N G Lieuwes; P N Span; S Haider; L Dubois; F Nguyen; H W van Laarhoven; F C G J Sweep; B G Wouters; P C Boutros; P Lambin
Journal:  Br J Cancer       Date:  2012-06-21       Impact factor: 7.640

Review 4.  Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3.

Authors:  Arno F Alpi; Viduth Chaugule; Helen Walden
Journal:  Biochem J       Date:  2016-10-15       Impact factor: 3.857

Review 5.  Trial Watch: Proteasomal inhibitors for anticancer therapy.

Authors:  Florine Obrist; Gwenola Manic; Guido Kroemer; Ilio Vitale; Lorenzo Galluzzi
Journal:  Mol Cell Oncol       Date:  2014-12-01

6.  UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells.

Authors:  Yan Qing Gong; Ding Peng; Xiang Hui Ning; Xin Yu Yang; Xue Song Li; Li Qun Zhou; Ying Lu Guo
Journal:  Oncol Lett       Date:  2016-10-10       Impact factor: 2.967

7.  UBE2T knockdown inhibits gastric cancer progression.

Authors:  Changjiang Luo; Yunyi Yao; Zeyuan Yu; Huinian Zhou; Lingyun Guo; Junqiang Zhang; Hongtai Cao; Genyuan Zhang; Yumin Li; Zuoyi Jiao
Journal:  Oncotarget       Date:  2017-05-16

8.  Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer.

Authors:  Mingxin Wen; Yongwon Kwon; Yongsheng Wang; Jian-Hua Mao; Guangwei Wei
Journal:  Oncotarget       Date:  2015-09-22

9.  UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway.

Authors:  Wei Hu; Lushan Xiao; Chuanhui Cao; Shengni Hua; Dehua Wu
Journal:  Oncotarget       Date:  2016-03-22

10.  UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma.

Authors:  Xiaoyuan Wang; Yang Liu; Xue Leng; Kui Cao; Wentao Sun; Jinhong Zhu; Jianqun Ma
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.